AVDL Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 0.38%, SMA50 0.67%, SMA200 40.29%). The stock’s 14-day RSI is 61.58 (firm momentum), while the ATR of 0.09 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -8.19% below its high and over 239.18% above its low.

Avadel Pharmaceuticals plc has 98.15 million shares outstanding. The public float is 86.22 million shares, elevated short interest at 2.38% of float. This equals 2.31 million shares. The short ratio is 1.6 days. Institutional investors hold 99.42% of the float. Insiders own 4.84%. Broadfin Healthcare Master Fund Ltd holds 4.13 million shares, Flynn James E has 952.26 thousand shares and ANDERSON MICHAEL S has 248.95 thousand shares. Over the past six months, insider transactions show net selling. They sold 11.11 million shares across 1 transactions.

Avadel Pharmaceuticals plc generated EPS of -$0.01 over the past year. Five-year average earnings growth is 10.39%. The latest quarter delivered EPS of -$0.05. The next quarter is forecast at $0.03. Next year's EPS is expected at $78.22. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 7 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $36.00 to $16.00. The high target offers 66.36% upside. The low target suggests -26.06% downside. The mean target is $21.70. This offers 0.28% upside. Avadel Pharmaceuticals plc earnings surprise history is a mixed track record. The quarter that ended March 02, 2026, missed forecasts by -162.5%. The prior quarter beat by -99.5%. Over the last six quarters, Apple has recorded several small beats. These include -50.0% in November 12, 2024.

Avadel Pharmaceuticals plc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.62. This means the shares are trading below this model’s fair value.

The stock is currently mid-range between its 52-week high and low $6.38 and $23.57. With a market capitalization of about $2.12 billion, Avadel Pharmaceuticals plc is classified as a mid-cap and shows higher-than-market volatility (beta ~1.31). Key stats such as the average daily volume over the past year has been around 2.42 million shares, trading with heavier-than-usual volume. Headquartered in Dublin, None, Avadel Pharmaceuticals plc operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Gregory J. Divis Jr., the company employs approximately 188 people and listed since June 07, 1996. Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States.

Avadel Pharmaceuticals plc (NASDAQ:AVDL) shares are flat -0.23% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Avadel Pharmaceuticals plc trading at a premium to the broader market with a P/E of 431.08. Analyst sentiment is cautious, with the majority of ratings in Equal-Weight territory and a mean price target of $17.88, suggesting -17.38% downside. Our AI forecast model points to short-term strength (0.69% over two weeks), a medium-term rise (57.58% over three months), and a longer-term gain (8.96% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Avadel Pharmaceuticals plc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.69%, with price expected at $21.79 by February 25, 2026, within a range of $21.68 to $21.90 3-Month Outlook: Projected rise of 57.58%, reaching $34.10 by May 12, 2026, with a range of $33.74 to $34.50. 1-Year Outlook: Projected gain of 8.96%, with price at $23.58 by February 11, 2027, within a range of $22.14 to $24.88.

Avadel Pharmaceuticals plc trades at a P/E ratio of 431.08, slightly above the S&P 500 average, with a price-to-sales ratio of 10.72 and a price-to-book ratio of 21.39 reflecting a rich premium to book value. The P/FCF stands at 77.14, also below market averages. Compared to sector medians, Avadel Pharmaceuticals plc P/S is trading rich, and the P/B is far lower than peers, underscoring the brand and earnings power premium investors assign to the stock.